Preemptive Bone Marrow Transplantation for FANCD1/BRCA2

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 10, 2015, Pages 1796-1801

  Khan, Nicholas E ^a   Rosenberg, Philip S ^a   Lehmann, Harold P ^b   Alter, Blanche P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRCA2; Decision analysis; Fanconi anemia; Markov model; Preemptive transplantation

Indexed keywords

BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN;

ARTICLE; BONE MARROW TRANSPLANTATION; CANCER DIAGNOSIS; CANCER RISK; CHILD; CLINICAL ARTICLE; DEATH; FEMALE; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA; MALE; MARKOV DECISION MODEL; MORTALITY; OVERALL SURVIVAL; PREEMPTIVE BONE MARROW TRANSPLANTATION; PRESCHOOL CHILD; SENSITIVITY ANALYSIS; SOLID TUMOR; STATISTICAL MODEL; ADVERSE EFFECTS; CORD BLOOD STEM CELL TRANSPLANTATION; DECISION SUPPORT SYSTEM; GENETICS; INFANT; KAPLAN MEIER METHOD; LEUKEMIA, MYELOID, ACUTE; MARKOV CHAIN; MUTATION; NEOPLASMS; NEOPLASTIC SYNDROMES, HEREDITARY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; QUALITY OF LIFE; RISK; THEORETICAL MODEL; TRANSPLANTATION CONDITIONING; TUMOR SUPPRESSOR GENE;

BONE MARROW TRANSPLANTATION; BRCA2 PROTEIN; CHILD, PRESCHOOL; CORD BLOOD STEM CELL TRANSPLANTATION; DECISION SUPPORT TECHNIQUES; GENES, BRCA2; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MARKOV CHAINS; MODELS, THEORETICAL; MUTATION; NEOPLASMS; NEOPLASTIC SYNDROMES, HEREDITARY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; QUALITY OF LIFE; RISK; TRANSPLANTATION CONDITIONING;

EID: 84941269091     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.07.006     Document Type: Article

References (33)

1. Shimamura A., Alter B.P. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev 2010, 24:101-122.
2. Alter B.P., Giri N., Savage S.A., et al. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol 2010, 150:179-188.
3. Alter B.P., Rosenberg P.S., Brody L.C. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. J Med Genet 2007, 44:1-9.
4. MacMillan M.L., Wagner J.E. Haematopoeitic cell transplantation for Fanconi anaemia - when and how?. Br J Haematol 2010, 149:14-21.
5. Peffault de L.R., Porcher R., Dalle J.H., et al. Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience. Blood 2013, 122:4279-4286.
6. Pasquini R., Carreras J., Pasquini M.C., et al. HLA-matched sibling hematopoietic stem cell transplantation for fanconi anemia: comparison of irradiation and nonirradiation containing conditioning regimens. Biol Blood Marrow Transplant 2008, 14:1141-1147.
7. Howlett N.G., Taniguchi T., Olson S., et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002, 297:606-609.
8. Wagner J.E., Tolar J., Levran O., et al. Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia and Fanconi anemia. Blood 2004, 103:3226-3229.
9. MacMillan M.L., Auerbach A.D., Wagner J.E. Risk of malignancy in patients with biallelic BRCA2 mutations. Pediatr Blood Cancer 2005, 44:539-540.
10. Chaudhury S., Auerbach A.D., Kernan N.A., et al. Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia. Br J Haematol 2008, 140:644-655.
11. Myers K., Davies S.M., Harris R.E., et al. The clinical phenotype of children with Fanconi anemia caused by biallelic FANCD1/BRCA2 mutations. Pediatr Blood Cancer 2011, 58:462-465.
12. Yeo C.J., Gilman A.L. Interleukin-2-induced graft-versus-leukemia for the treatment of AML in a BRCA2 Fanconi anemia patient. J Pediatr Hematol Oncol 2013, 36:e78-e80.
13. Ayas M., Saber W., Davies S.M., et al. Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia. J Clin Oncol 2013, 31:1669-1676.
14. Mitchell R., Wagner J.E., Hirsch B., et al. Haematopoietic cell transplantation for acute leukaemia and advanced myelodysplastic syndrome in Fanconi anaemia. Br J Haematol 2014, 164:384-395.
15. Alter B.P. Fanconi anemia and the development of leukemia. Best Pract Res Clin Haematol 2014, 27:214-221.
16. Smith C.M. Origin and uses of primum non nocere-above all, do no harm!. J Clin Pharmacol 2005, 45:371-377.
17. Dewire M.D., Ellison D.W., Patay Z., et al. Fanconi anemia and biallelic BRCA2 mutation diagnosed in a young child with an embryonal CNS tumor. Pediatr Blood Cancer 2009, 53:1140-1142.
18. Bodd T.L., Van G.M., Eiklid K., et al. Fanconi anaemia, BRCA2 and familial considerations - follow up on a previous case report. Acta Paediatr 2010, 99:1741-1743.
19. Kopic S., Eirich K., Schuster B., et al. Hepatoblastoma in a 4-year-old girl with Fanconi anaemia. Acta Paediatr 2011, 100:780-783.
20. Beck J.R., Pauker S.G. The Markov process in medical prognosis. Med Decis Making 1983, 3:419-458.
21. Cutler C.S., Lee S.J., Greenberg P., et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004, 104:579-585.
22. Pidala J., Anasetti C., Kharfan-Dabaja M.A., et al. Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009, 15:1415-1421.
23. Rosenberg P.S., Socie G., Alter B.P., Gluckman E. Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants. Blood 2005, 105:67-73.
24. Briggs A., Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998, 13:397-409.
25. Gaynor J.J., Feuer E.J., Tan C.C., et al. On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data. J Amer Stat Assoc 1993, 88:400-409.
26. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
27. Pai S.Y., Logan B.R., Griffith L.M., et al. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med 2014, 371:434-446.
28. Boelens J.J., Wynn R.F., O'Meara A., et al. Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant 2007, 40:225-233.
29. Ayas M., Siddiqui K., Al-Jefri A., et al. Factors affecting the outcome of related allogeneic hematopoietic cell transplantation in patients with Fanconi Anemia. Biol Blood Marrow Transplant 2014, 20:1599-1603.
30. Kodish E., Lantos J., Stocking C., et al. Bone marrow transplantation for sickle cell disease. A study of parents' decisions. N Engl J Med 1991, 325:1349-1353.
31. Pidala J., Anasetti C., Jim H. Quality of life after allogeneic hematopoietic cell transplantation. Blood 2009, 114:7-19.
32. Willard V.W., Leung W., Huang Q., et al. Cognitive outcome after pediatric stem-cell transplantation: impact of age and total-body irradiation. J Clin Oncol 2014, 32:3982-3988.
33. Tanzi E.M. Health-related quality of life of hematopoietic stem cell transplant childhood survivors: state of the science. J Pediatr Oncol Nurs 2011, 28:191-202.